Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep 27;7(1):338.
doi: 10.1038/s41392-022-01187-5.

Cis-regulatory decoy disrupts autorepression: a potential escape-resistant anti-viral therapy

Jia Hu #  1 , Yuanqin Min #  1 , Xiulian Sun  2
Affiliations
Comment

Cis-regulatory decoy disrupts autorepression: a potential escape-resistant anti-viral therapy

Jia Hu et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Synthetic “open-loop lethality” makes autorepression circuitry the viral Achilles’ heel. Virus-encoded specific protein can serve as trans-acting factor that binds to the cis-repression sequence on viral genome and auto-represses viral transcription to avoid aberrant viral protein expression, thus maintaining homeostasis beneficial for virus infection (left). Artificially synthesized nucleic acid decoys (molecular mimics of the cis-regulatory binding sites) can disrupt the normal negative feedback, raising viral protein expression to cytotoxic levels and leading to clearance of infected cells by apoptosis (right). This synthetic “open-loop lethality” turns the viral autorepression circuitry into a fatal weakness of virus life cycle, representing a novel and escape-resistant antiviral strategy
See this image and copyright information in PMC

Comment on

References

    1. Chaturvedi S, et al. Disrupting autorepression circuitry generates “open-loop lethality” to yield escape-resistant antiviral agents. Cell. 2022;185:2086–2102.e2022. doi: 10.1016/j.cell.2022.04.022. - DOI - PMC - PubMed
    1. Morishita R, et al. A gene-therapy strategy using a transcription factor decoy of the E2f binding-site inhibits smooth-muscle proliferation in-vivo. Proc. Natl Acad. Sci. USA. 1995;92:5855–5859. doi: 10.1073/pnas.92.13.5855. - DOI - PMC - PubMed
    1. Hecker M, Wagner AH. Transcription factor decoy technology: a therapeutic update. Biochem. Pharm. 2017;144:29–34. doi: 10.1016/j.bcp.2017.06.122. - DOI - PubMed
    1. Mulamba GB, et al. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922) Antimicrob. Agents Chemother. 1998;42:971–973. doi: 10.1128/AAC.42.4.971. - DOI - PMC - PubMed

MeSH terms